X
[{"orgOrder":0,"company":"Develco Pharma","sponsor":"HMNC Brain Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"HMNC Brain Health and Develco Pharma Announce Last Patient Being Randomized in Oral Prolonged-Release Ketamine (KET01) Trial for Treatment-Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"March 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"},{"orgOrder":0,"company":"Develco Pharma","sponsor":"HMNC Brain Health","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Ketabon GmbH Reports Top-Line Results from Phase 2 Trial of Take-at-Home, Oral Ketamine Option for Treatment-Resistant Depression","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase II","country":"SWITZERLAND","productType":"Small molecule","productStatus":"Approved","date":"August 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Develco Pharma
Filters
Companies By Therapeutic Area
Details:
KET01 is an oral prolonged-release ketamine formulation, a rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia typically in combination with a muscle relaxant. It is being currently developed for treatment-resistant depression.
Lead Product(s):
Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology
Product Name: KET01
Highest Development Status: Phase II
Product Type: Small molecule
Recipient:
HMNC Brain Health
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
August 14, 2023
Details:
KET01 is an oral prolonged-release ketamine formulation, a rapid-acting general anesthetic and NMDA receptor antagonist used for induction of anesthesia typically in combination with a muscle relaxant. It is being currently developed for treatment-resistant depression.
Lead Product(s):
Ketamine Hydrochloride
Therapeutic Area: Psychiatry/Psychology
Product Name: Ketabon
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
HMNC Brain Health
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 28, 2023